Simon Hellier
Wellcome Trust Centre for Human Genetics
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Simon Hellier.
Genes and Immunity | 2003
Suzanne Knapp; Lj Yee; Angela J. Frodsham; Branwen J. Hennig; Simon Hellier; Lyna Zhang; Mark Wright; M Chiaramonte; M Graves; Howard C. Thomas; Avs Hill; Mark Thursz
Interferon stimulates the expression of a number of genes encoding enzymes with antiviral activities, including myxovirus resistance-1 (MxA), 2-5-oligoadenylate synthetase 1 (OAS-1) and double-stranded RNA-dependent protein kinase (PKR). We examined whether polymorphisms in these genes influenced the outcome of hepatitis C virus (HCV) infection. We observed a lower frequency of the GG genotype at position −88 in the MxA gene promoter in self-limiting HCV infection (OR=0.56; 95% CI: 0.35–0.8; P=0.010) and in nonresponders to therapy (OR=0.49; 95% CI: 0.25–0.95; P=0.020). This genotype predominantly influenced the outcome of treatment in patients with viral genotype 1 (OR=0.22 95% CI: 0.07–0.67; P=0.002). A polymorphism in the 3′-untranslated region of the OAS-1 gene was associated with outcome of infection (GG genotype less frequent in self-limiting infection: OR=0.43; 95% CI: 0.21–0.86; P=0.010). A polymorphism at position −168 in the promoter region of the PKR gene was associated with self-limiting infection (CT genotype: OR=2.75; 95% CI: 1.45–5.24; P=0.002). Further associations were found with a CGG trinucleotide repeat in the 5′UTR region of the PKR gene. Polymorphisms in the interferon-induced genes, MxA, OAS-1 and PKR appear thus associated with HCV outcome.
Gut | 2003
Mark Wright; Robert Goldin; Simon Hellier; Suzanne Knapp; Angela J. Frodsham; Branwen J. Hennig; Adrian V. S. Hill; R Apple; S Cheng; Howard C. Thomas; Mark Thursz
Background: The rate of progression to cirrhosis varies among individuals chronically infected with the hepatitis C virus (HCV). Coagulation pathway activation in models of hepatic fibrosis suggests variation in coagulation pathway components may influence the rate of fibrosis. We hypothesised that polymorphisms of the coagulation factors II and V affect the rate of progression to cirrhosis in HCV infected subjects. Methods: We studied the relationship between rate of fibrosis (calculated by dividing the fibrosis stage by duration of infection) and genotypes of specific coagulation pathway genes in 352 White European patients infected with HCV. Genotyping was performed using reverse line blot hybridisation. Results: The rate of fibrosis was significantly higher in patients with the factor V Leiden genotype (Arg560Gln) (ANOVA, p=0.004). In disease association studies, a significant association was seen (Fisher’s exact test, p=0.029; odds ratio 3.28 for fast progression to cirrhosis (expected to reach cirrhosis in less than 30 years) if heterozygous for factor V Leiden). No associations were seen between factor II genotype and fibrosis rate. Conclusions: Possession of the factor V Leiden polymorphism significantly increases the risk of rapid disease progression in HCV, suggesting a role for the coagulation system in the pathogenesis of fibrotic liver disease.
Genes and Immunity | 2002
Branwen J. Hennig; Simon Hellier; Angela J. Frodsham; Lyna Zhang; Paul Klenerman; Suzanne Knapp; Mark Wright; Howard C. Thomas; Mark Thursz; Adrian V. S. Hill
The low-density lipoprotein receptor (LDLR) has been proposed to promote hepatitis C virus endocytosis and the cell membrane protein CD81 may also promote HCV host cell entry. The CD81 gene was sequenced to screen for novel polymorphisms, but no SNPs were identified. Polymorphisms within the LDLR gene are associated with the pathogenesis of familial hypercholesterolemia, atherosclerosis and obesity. We therefore studied genetic variation within the LDLR gene and clinical features of hepatitis C infection. An amino acid change in exon 8 was associated with severity of fibrosis; a SNP in exon 10 correlated with viral clearance and overall inflammation, and a SNP in the 3′UTR appeared to influence treatment response. There were no other significant associations between any of the SNPs studied and the clinical measures of hepatitis C infection. We furthermore report on linkage disequilibrium within the gene and haplotype frequencies in our population. Our findings support a possible role for the LDLR in the modulation of disease progression by affecting immune responses, rather than functioning as receptor for HCV.
Liver International | 2007
Branwen J. Hennig; Angela J. Frodsham; Simon Hellier; Susanne Knapp; Leland J. Yee; Mark Wright; Lyna Zhang; Howard C. Thomas; Mark Thursz; Adrian V. S. Hill
Background: Two receptor chains, IL‐10RA and IL‐10RB, are known to mediate the functions of interleukin‐10 (IL‐10), which has been shown to be involved in the progression of persistent hepatitis C virus (HCV) infection. Little information is available on the role of host genetic variation in IL‐10 receptor genes and outcome of HCV infection. IL‐22, an IL‐10 homologue, shares the IL‐10RB receptor chain with IL‐10 and has antiviral properties. We investigated the possible role of polymorphisms in the IL‐10RA and IL‐22 genes in hepatitis C disease pathogenesis.
Hepatology | 2003
Simon Hellier; Angela J. Frodsham; Branwen J. Hennig; Paul Klenerman; Suzanne Knapp; Patricia A. Ramaley; Jack Satsangi; Mark Wright; Lyna Zhang; Howard C. Thomas; Mark Thursz; Adrian V. S. Hill
Proceedings of the National Academy of Sciences of the United States of America | 2006
Angela J. Frodsham; Lyna Zhang; Uga Dumpis; Nor Azizah Mohd Taib; Steve Best; Andrew Durham; Branwen J. Hennig; Simon Hellier; Susanne Knapp; Mark Wright; M. Chiaramonte; John I. Bell; Mary Graves; Hilton Whittle; Howard C. Thomas; Mark Thursz; Adrian V. S. Hill
Hepatology | 2003
Simon Hellier; Angela J. Frodsham; Branwen J. Hennig; Suzanne Knapp; Mark Wright; Lyna Zhang; Howard C. Thomas; Mark Thursz; Adrian V. S. Hill
Journal of Hepatology | 2002
Mark Wright; Robert Goldin; Simon Hellier; Adrian V. S. Hill; Raymond Apple; Susanne Cheng; Howard C. Thomas; Mark Thursz
Journal of Hepatology | 2000
Simon Hellier; M. Martin-Ginolhac; R. Phillips; Roger W. Chapman; Paul Klenerman
Gastroenterology | 2000
Simon Hellier; Manon Martin-Ginolhac; Rodney E. Phillips; Roger W. Chapman; Paul Klenerman